CWM
VRTX icon

Centric Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Centric Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-885
Closed -$256K – 122
2022
Q3 		$256K Buy
+885
New +$255K 0.1% 105

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Centric Wealth Management's VRTX Position: Q4 2022 in Review

Centric Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2022, closing a stake of 885 shares — an estimated $256K sold.

Centric Wealth Management first reported a position in VRTX in Q3 2022 and held it in 1 quarter. The position peaked at $256K in Q3 2022. 1,222 funds tracked by Wall St. Rank hold VRTX as of Q4 2022.

  • Centric Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Centric Wealth Management sold 885 Vertex Pharmaceuticals shares in Q4 2022, an estimated $256K.
  • Centric Wealth Management first reported a position in Vertex Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Centric Wealth Management's Vertex Pharmaceuticals position peaked at $256K in Q3 2022.
  • 1,222 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2022.

Based on Centric Wealth Management's 13F filing for Q4 2022, filed 4 Jan 2023.